MedTrace Logo

Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

NCT04533022 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.

Conditions

Interventions

DRUG

C21

C21 100 mg BID (twice daily)

Sponsors & Collaborators

  • Orphan Reach Ltd.

    collaborator INDUSTRY

  • Vicore Pharma AB

    lead INDUSTRY

Principal Investigators

  • Joanna Porter, MD · Respiratory Medicine, University College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-13
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • India
  • Russia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04533022 on ClinicalTrials.gov